Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells
- 22 October 2009
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 114 (17), 3513-3523
- https://doi.org/10.1182/blood-2009-03-191304
Abstract
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) provide remarkable cellular platforms to better understand human hematopoiesis and to develop clinically applicable hematopoietic cell–based therapies. Over the past decade, hESCs have been used to characterize molecular and cellular mechanisms underpinning the differentiation of hematopoietic progenitors and mature, functional hematopoietic cells. These advances are now poised to lead to clinical translation of hESC- and iPSC-derived hematopoietic cells for novel therapies in the next few years. On the basis of areas of recent success, initial clinical use of hematopoietic cells derived from human pluripotent stem cells will probably be in the areas of transfusion therapies (erythrocytes and platelets) and immune therapies (natural killer cells). In contrast, efficient development and isolation of hematopoietic stem cells capable of long-term, multilineage engraftment still remains a significant challenge. Technical, safety, and regulatory concerns related to clinical applications of human PSCs must be appropriately addressed. However, proper consideration of these issues should facilitate and not inhibit clinical translation of new therapies. This review outlines the current status of hematopoietic cell development and what obstacles must be surmounted to bring hematopoietic cell therapies from human PSCs from “bench to bedside.”This publication has 121 references indexed in Scilit:
- Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming ProteinsCell Stem Cell, 2009
- Noncanonical Wnt Signaling Orchestrates Early Developmental Events toward Hematopoietic Cell Fate from Human Embryonic Stem CellsCell Stem Cell, 2009
- Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming FactorsCell, 2009
- Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3Experimental Hematology, 2008
- Disease-Specific Induced Pluripotent Stem CellsCell, 2008
- Trophoblast Differentiation Defect in Human Embryonic Stem Cells Lacking PIG-A and GPI-Anchored Cell-Surface ProteinsCell Stem Cell, 2008
- Hematopoiesis: An Evolving Paradigm for Stem Cell BiologyCell, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasisNature, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006